Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention

European Heart Journal

Volumn 29, Issue 15, 2008, Pages 1843-1850

  Niccoli, Giampaolo ^a   Giubilato, Simona ^a   Russo, Eleonora ^a   Spaziani, Cristina ^a   Leo, Andrea ^a   Porto, Italo ^a   Leone, Antonio M ^a   Burzotta, Francesco ^a   Riondino, Silvia ^b   Pulcinelli, Fabio ^b   Biasucci, Luigi M ^a   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute myocardial infarction; No reflow; Platelets; Primary percutaneous coronary intervention; Thromboxane A2

Indexed keywords

ABCIXIMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THROMBOXANE A2;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLOOD FLOW; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID BLOOD LEVEL; FEMALE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; THROMBUS ASPIRATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; ELECTROCARDIOGRAPHY; ENDOTHELIN-1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; RISK ASSESSMENT; THROMBOXANE A2; TREATMENT OUTCOME;

EID: 48749130828     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn325     Document Type: Article

References (31)

1. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-662.
2. Kusama I, Hibi K, Kosuge M, Nozawa N, Ozaki H, Yano H, Sumita S, Tsukahara K, Okuda J, Ebina T, Umemura S, Kimura K. Impact of plaque rupture on infarct size in ST-segment elevation anterior acute myocardial infarction. J Am Coll Cardiol 2007;50:1230-1237.
3. Xu Y, Huo Y, Toufektsian MC, Ramos SI, Ma Y, Tejani AD, French BA, Yang Z. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2006;290:H692-H699.
4. Heindl B, Zahler S, Welsch U, Becker BF. Disparate effects of adhesion and degranulation of platelets on myocardial and coronary function in postischaemic hearts. Cardiovasc Res 1998;38:383-394.
5. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-2383.
6. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991;68:11B- 15B.
7. TIMI Study Group. The thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985;312:932- 936.
8. Van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Myocardial Infarction Study Group. Circulation 1998;97:2302-2306.
9. Gibson CM, Murphy SA, Morrow DA, Aroesty JM, Gibbons RJ, Gourlay SG, Barron HV, Giugliano RP, Antman EM, Braunwald E. Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Am Heart J 2004;148:336-340.
10. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985;5:587-592.
11. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E, TIMI Study Group. Combination therapy with abcixamab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 2001;103:2550-2554.
12. Schröder R, Dissmann R, Brüggemann T, Wegscheider K, Linderer T, Tebbe U, Neuhaus KL. Extent of early ST-segmental elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994;24:384-391.
13. Harrell FE Jr. Predicting Outcomes: Applied Survival Analysis and Logistic Regression. Charlottesville: University of Virginia; 1997.
14. Rigby AS. Statistical methods in epidemiology: I. Statistical errors in hypothesis testing. Disabil Rehabil 1998;20:121-126.
15. Perneger TV. What's wrong with Bonferroni adjustments. Br Med J 1998;316:1236-1238.
16. Niccoli G, Lanza GA, Shaw S, Romagnoli E, Gioia D, Burzotta F, Trani C, Mazzari MA, Mongiardo R, De Vita M, Rebuzzi AG, Lüscher TF, Crea F. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J 2006;27:1793-1798.
17. Chaitman B, Lim B. No reflow and the quest to achieve optimal perfusion during the acute phase of myocardial infarction. J Am Coll Cardiol 2004;44:313-315.
18. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004;110:1392-1397.
19. Valles J, Santos MT, Fuset MP, Moscardo A, Ruano M, Perez F, Piñon M, Breña S, Aznar J. Partial Inhibition to platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2007;99:19-25.
20. Smith EF 3rd, Griswold DE, Egan JW, Hillegass LM, DiMartino MJ. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505. J Cardiovasc Pharmacol 1989;13:715-722.
21. Huczek Z, Filipiak KJ, Kochman J, Piatkowski R, Grabowski M, Roik M, Malek LA, Jaworski P, Opolski G. Baseline platelet reactivity in acute myocardial infarction treated with prymari angioplasty- influence on myocardial reperfusion, left ventricular performance, and clinical events. Am Heart J 2007;154:62-70.
22. Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, Catozzi L, Malagutti P, Anselmi M, Vassanelli C, Scapoli G, Ferrari R. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention. J Am Coll Cardiol 2006;48:2178-2185.
23. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991;338:1409-1411.
24. Huczek Z, Kochman J, Filipiak KJ, Horszczaruk GJ, Grabowski M, Piatkowski R, Wilczynska J, Zielinski A, Meier B, Opolski G. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005;46:284-290.
25. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002;99:7634-7639.
26. Kirtane AJ, Bui A, Murphy SA, Barron HV, Gibson CM. Association of peripheral neutrophilia with adverse angiographic outcomes in ST-elevation myocardial infarction. Am J Cardiol 2004;93:532-536.
27. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008;358:557-567.
28. Osende JI, Shimbo D, Fuster V, Dubar M, Badimon JJ. Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost 2004;2:492-498.
29. Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003;41:1198-1204.
30. Fiddler GI, Lumley P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation 1990;81(Suppl. 1):169-178.
31. Grover GJ, Schumaker WA. Effect of the thromboxane A2 receptor antagonist SQ 30, 741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve. J Pharmacol Exp Ther 1989;248:484-491.